These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 34987107)
1. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension. Kuzeytemiz M; Tenekecioglu E J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107 [TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system. Sandhu AT; Kohsaka S; Lin S; Woo CY; Goldstein MK; Heidenreich PA Am Heart J; 2021 Oct; 240():46-57. PubMed ID: 34126079 [TBL] [Abstract][Full Text] [Related]
3. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis. Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513 [TBL] [Abstract][Full Text] [Related]
4. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. Choksi TT; Zhang H; Chen T; Malhotra N Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074 [TBL] [Abstract][Full Text] [Related]
6. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202 [TBL] [Abstract][Full Text] [Related]
7. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120 [TBL] [Abstract][Full Text] [Related]
8. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study. Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985 [TBL] [Abstract][Full Text] [Related]
9. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988 [TBL] [Abstract][Full Text] [Related]
10. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615 [TBL] [Abstract][Full Text] [Related]
12. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients. Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713 [TBL] [Abstract][Full Text] [Related]
14. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171 [TBL] [Abstract][Full Text] [Related]
15. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction. Raposeiras-Roubín S; Abu-Assi E; Cespón-Fernández M; Ibáñez B; García-Ruiz JM; D'Ascenzo F; Simao Henriques JP; Saucedo J; Caneiro-Queija B; Cobas-Paz R; Muñoz-Pousa I; Wilton SB; González Juanatey JR; Kikkert WJ; Núñez-Gil I; Ariza-Solé A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Gaita F; Huczek Z; Nie SP; Yan Y; Fujii T; Correia L; Kawashiri MA; Kedev S; Southern D; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Giordana F; Kowara M; Filipiak K; Wang X; Fan JY; Ikari Y; Nakahayshi T; Sakata K; Yamagishi M; Kalpak O; Íñiguez-Romo A Rev Esp Cardiol (Engl Ed); 2020 Feb; 73(2):114-122. PubMed ID: 31105064 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway. Felber R; New W; Riskin SI Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704 [TBL] [Abstract][Full Text] [Related]
17. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928 [TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367 [TBL] [Abstract][Full Text] [Related]
19. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S; Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G; Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]